CD8A and Patent ductus arteriosus: Our data from PDA engrafted immune competent mice treated with CD8 neutralizing antibody or engrafted to Rag-deficient mice suggested that the anti-tumor effects of STING agonist required both CD8+ T cells as well as accessory innate cells.